Silver-enhanced in-situ hybridization (SISH) is an emerging tool for the determination of the Her-2/neu amplification status in breast cancer. SISH is technically comparable to fluorescence in-situ hybridization (FISH) but does not require a fluorescence microscope for its interpretation. Although recent studies on histologic evaluations of SISH are promising, we aimed to evaluate its performance on 71 cytologic breast cancer specimens with the new combined Her-2/Chr17 probe. Her-2/ neu status as routinely determined by FISH was available for all patients. We found SISH signals in cytologic cell blocks and smear specimens easy to evaluate in most cases. Small numbers of tumor cells and difficulties in identifying tumor cells in lymphocyte-rich backgrounds were limiting factors. Her-2/neu status, as determined by Her-2/Chr17 SISH, was basically identical to the results of the corresponding FISH. The discrepancies were mainly owing to the heterogeneity of Her-2/neu amplification in the tumor tissue. Interobserver agreement for the SISH evaluation was high (k value: 0.972). We conclude that Her-2/Chr17 SISH is a useful and accurate method for the evaluation of the Her-2/neu gene amplification status in cytologic breast cancer specimens, particularly in metastatic breast cancer lesions. The advantages of signal permanency and brightfield microscopic result interpretation make this technique an attractive alternative to the current FISH-based gold standard.
S ilver-enhanced in situ-hybridization (SISH) is a recently introduced new, bright-field in-situ hybridization technique for the detection of DNA signals, mainly used for cancer genotyping. The technique is based on enzymatic metallography and metallic silver deposition. 7 The resulting silver complex deposits are stable over time and, furthermore, allow the surgical pathologist to assess the signal with conventional bright-field microscopes instead of fluorescence microscopes necessary for fluorescence in-situ hybridization (FISH) . Until now, the SISH technique has mainly been promoted for the assessment of the Her-2/neu amplification status in breast cancer patients. The most recent SISH version allows for a combined detection of Her-2/neu and chromosome 17 including a chromogenic detection for the latter one.
The identification of invasive breast carcinomas with the amplification of the human epidermal growth receptor 2 gene (ERBB2 or Her-2/neu) has, like the assessment of the hormone receptor status, become an essential standard procedure for the assessment of newly diagnosed breast cancers. 6, 8 This is mainly owing to the availability of effective treatment of tumors with overexpression of Her-2 with humanized anti-Her-2 antibodies. Overexpression of Her-2/neu is found in approximately 15% of breast cancers and it is only in these patients that the above-mentioned therapy is beneficial and cost effective. 1, 5, 11, 15 The additional costs for an anti-Her-2 antibody therapy have been estimated between US$40,000 and 50,000 (equaling h25,000 to 35,000). 10 Therefore, high reliability and robustness in the assessment of the Her-2/neu amplification status are mandatory.
Fine-needle aspirations (FNA) or body cavity fluids containing breast cancer cells are common in routine cytologic work. The role of FNA in the diagnosis of metastatic or disseminated disease is undisputed, whereas the diagnosis of the primary tumor is more controversial, being well established in only a few specialized centers. 12, 16 Requests for testing of Her-2/neu amplification status on cytologic specimens, mainly in the setting of a metastatic disease, have been increasing constantly over the last few years.
According to the last American Society of Clinical Oncology Guidelines, 2 different ways of testing are commonly used to determine the Her-2 status in the surgical pathology specimens. 19 They comprise the detection of the Her-2 protein and/or of the Her-2/neu gene amplification status by immunohistochemistry or by fluorescence, chromogenic or silver-labeled in-situ hybridization methods. On account of insufficiencies of the immunohistochemistry in terms of interobserver and interlaboratory variability, the in-situ hybridization method, particularly the FISH analysis, is currently regarded as the gold standard. 17 However, the need for special microscopic equipment and the rather quick fading of fluorochromes over time are relevant disadvantages of the FISH technique.
In this study, we analyzed the usability and reliability of the SISH technique for the determination of the Her-2/neu amplification status in different cytologic breast cancer specimens in comparison with corresponding FISH results.
MATERIALS AND METHODS

Patients and Samples
Seventy-one patients diagnosed with breast cancer at the Division of Cytology of the Institute of Surgical Pathology of the University Hospital Zurich, with known Her-2 FISH status, were included in this study. Twentythree of the specimens originated from 2006 to 2008 and were selected because of their amplified Her-2/neu status in FISH. The remaining 48 specimens were from consecutive patients in 2009. The study was approved by the project review board at our institution and no further ethical approvals were necessary. The median patient age was 62 years (range: 29 to 86 y). The cytologic samples consisted of 34 (47.9%) FNAs of primary breast tumors, 25 (35.2%) FNAs of metastases (22 lymph nodes and 3 soft tissue masses), and 11 (15.5%) body cavity fluids (9 pleural effusions and 2 abdominal effusions) as well as 1 mammary secretion. For 64 patients the histologic data on the primary tumor were available: 58 (90.6%) had invasive ductal carcinomas, 4 (6.3%) had invasive lobular carcinomas, and 2 (3.1%) were carcinomas of other histologic types. The pT tumor status was pT1: 22 cases (34.4%), pT2: 30 (46.9%), pT3: 8 (12.5%), and pT4: 4 (6.3%), respectively. The histologictumor grade was G1: 2 (3.1%), G2: 18 (28.1%), and G3: 42 (65.6%). For 2 cases no grading was given because of too small amounts of tumor in the core biopsy specimens. The results of the Her-2/neu FISH analysis were available for all patients. In 47 (66.2%) cases FISH and SISH analyses were performed on biopsies and/or FNAs of exactly the same primary (36 of 47 cases) or metastatic (6 of 47 cases) tumor nodules or fluid specimens (5 of 47 cases). The combinations of specimen preparations for these 47 cases were as follows: 19 (40.4%) cases: SISH on cell block and FISH on histologic specimen; 11 (23.4%) cases: SISH on smear and FISH on histologic specimen; 16 (34.0%) cases: SISH and FISH on cell block; and 1 (2.1%) case: SISH on smear and FISH on cell block.
In the remaining 24 cases the SISH was mostly (79.2%) performed on metastatic deposits whereas the FISH was performed on the primary tumor. In 4 cases SISH and FISH were performed on different metastatic deposits and in 1 case SISH was performed on the primary tumor and FISH on the metastasis. The combinations of specimen preparations for these 24 cases were as follows: 12 (50.0%) cases: SISH on cell block and FISH on histologic specimen; 11 (45.8%) cases: SISH on smear and FISH on histologic specimen; and 1 (4.2%) case: SISH and FISH on cell block.
The median time lag between the specimen taken for the FISH and the one taken for SISH analysis was 1 week. Only in 4 cases was this time lag more than 8 weeks.
SISH
SISH was performed according to the manufacturers' protocol either on paraffin slides from the cytology cell blocks or on Papanicolau stained direct smears. Cytologic cell blocks were prepared by coagulating the FNA/fluid cell pellets with a mixture of plasma and thrombin and further standard processing of the clot to paraffin blocks. The INFORM HER-2 DNA probe was detected with the ultraView SISH Detection Kit and INFORM Chromosome 17 probe with the ultraView AP red SISH Detection Kit (780 to 4332 and 780 to 4331, Ventana Medical Systems, Tucson, AZ). The whole process was completely automated using Ventana's Benchmark autostainers. The protocol of SISH staining has been described before. 7 The specimens were briefly counterstained with Ventana Hematoxilin II. 
SISH Scoring
The SISH signals were scored by counting the signals for Her-2 (black) and chromosome 17 (red) according to the manufacturer's recommendation in 20 cancer cell nuclei. The Her-2 signals were divided by the chromosome 17 signals. According to the manufacturer's manual the threshold for amplification was a value larger than 2.2. Results below 1.8 were considered nonamplified and those between both values equivocal. The evaluations were carried out independently by 2 pathologists (F.R.F. and P.K.B.) on conventional Zeiss Axioscope 40 Microscopes with Â 400 magnification (Carl Zeiss MicroImaging, Jena, Germany). Both pathologists were blinded to the clinicopathologic parameters, earlier FISH results, and the SISH results of each other.
RESULTS
SISH Results
Altogether, 50 Her-2 SISH results were obtained from cytologic cell blocks and 23 from direct smears. For 2 patients the analysis was performed on the cell block and on the cytologic smear. In these 2 patients the SISH results were identical on both media for both evaluating pathologists and were also consistent with the FISH results.
The SISH signals were easily detectable in almost all cases ( Fig. 1) and both red and black signals were unchanged in intensity after 7 months. In comparison with the black Her-2 signals the red chromosome 17 signals appeared generally stronger and bigger. In terms of Her-2/neu amplification status in the SISH analyses, 39 (54.9%) cases were considered nonamplified, 31 (43.7%) were amplified, and 1 case (1.4%) was considered equivocal.
Comparison of Her-2 SISH and FISH Results
From the 39 cases that were considered nonamplified in the SISH analysis, 36 (92.3%) were also nonamplified in the FISH analysis (Table 1) .
Three cases (7.7%) were considered amplified in the FISH analysis. One of the discrepant SISH analyses was applied on a cell block, the other 2 on cytologic smears. All 3 samples corresponded to FNA of the breast and corresponding FISH was performed on the histologic sample of the same tumor nodule. On review of these cases, in 2 cases the FISH analysis showed only heterogeneous Her-2/neu amplification with several clearly nonamplified tumor cells. On review of the corresponding SISH analyses in 1 of the cases very few definitely amplified cells could be detected. The third case was unequivocally amplified in the histologic FISH analysis. However, the smear showed prominent air-drying artifacts, which were already noted during evaluation and it additionally included cells with polysomy. Nevertheless, in the informed review as well no amplified cells could be detected in the SISH in this case.
From the 31 cases that were amplified in the SISH, 30 (96.8%) were also considered amplified in the FISH with 1 being considered equivocal. The equivocal FISH (histologic sample of the same tumor nodule) was considered to be amplified in the report owing to heterogeneity.
One case was considered equivocal in the SISH whereas it was considered amplified in the FISH analysis (both on cell blocks of the same tumor nodule). The repeat of the FISH result showed definitely amplified cells but was also rather heterogeneous.
Interobserver consistency between the 2 pathologists independently evaluating Her-2 SISH was excellent with a k value of 0.972. The only discrepant case was considered amplified by one and nonamplified by the other pathologist. The FISH analysis in this case was considered amplified. In the revision of the case on a multiheaded microscope consensus in terms of amplifica-tion was reached. However, both SISH and FISH were only just above the positivity limit for this case.
DISCUSSION
In this study, the Her-2/neu amplification status of a series of breast cancer cases was examined in the cytology specimens by the recently introduced SISH technique. Results of our study showed high interobserver reproducibility in the SISH signal interpretation between the 2 cytologists and a high concordance with FISH results.
Despite being more expensive, the in-situ hybridization techniques are considered to be advantageous in terms of reliability for the determination of the predictively important Her-2 status in breast cancer patients in comparison with immunohistochemistry. 17 The costs of SISH are comparable with that of FISH. On the Ventana platform, SISH is completely automated, which ensures consistency and reproducibility of methodology and results. SISH results were available in up to 6 hours. The major advantage of Her-2 SISH over the current standard FISH is the stability of the signal over time. Furthermore, unlike with FISH, conventional bright-field microscopes are sufficient for evaluation, which is clearly an advantage over timeconsuming FISH evaluation sessions.
The first evaluation of Her-2 SISH was performed by Dietel et al 7 on breast cancer tissue samples. In the meantime several other groups were able to validate these results on breast cancer tissue. [2] [3] [4] 9, 18 Like Dietel et al, they found good reproducibility of the results and high concordance with immunohistochemistry, polymerase chain reaction, and with other in-situ techniques (including FISH). Our results are strongly consistent with those of the research groups mentioned in terms of reliability and interobserver consistency. In line with these studies we experienced only a few equivocal cases. This may be owing to the fact that about one-third of the cases were selected on the basis of their known positivity.
A general matter of concern regarding the SISH technology could be that in contrast with FISH results, which were often analyzed by one person or a small group of people in an institution, SISH signals would theoretically be readable by any surgical pathologist during routine work. This restriction, implied in the FISH analysis, which is also recommended by national and international breast cancer working groups, is advantageous in terms of interobserver consistency. Therefore, although the consistency in our study was high, specialization and division of work, as is common practice in most breast centers, should also be applied for SISH analyses.
In contrast to earlier studies, our study assessed the usability of SISH in cytologic specimens. The use of hormone receptor analyses and other immunohistochemical stains on cytologic specimens has already been shown long ago. 13 Recently, Nassar et al 14 evaluated new monoclonal antibodies against hormone receptors and Her-2 on cell blocks. Our results show for the first time that Her-2/neu amplification status assessments with SISH can be performed with high reliability on cytologic specimens. The rare discrepancies were mostly owing to the intratumoral heterogeneity among the cells, an inherent tumor characteristic.
Many specimens in most modern cytologic laboratories are nowadays preferentially prepared and evaluated simultaneously on both direct smears and cell blocks, allowing for the analysis of different aspects of the tissue that is examined. However, the examiner interpreting study results must not forget the inherent important biological differences between 3-dimensional direct smears of intact cells and 2-dimensional cuts of the tissue. During the cutting of the specimen for histologic processing, substantial parts of the cells are discarded and will not be appreciated on later microscopic analysis. This truncation effect must be taken into account in the quantitative studies pertaining to the content of the nucleus, such as counting signals of an in-situ hybridization reaction. The consideration of the cell geometry plays an important role in evaluating chromosome polysomy, as shown by Zlobec 20 for EGFR FISH, in which the cutoff values established for the histology specimen must not be applied when interpreting the signals on the cytology specimens from nonsmall cell lung cancer. The effect of the sample type (smear vs. paraffin cut) on evaluating gene amplification is less pronounced and could not be observed in our study group.
An important biologic point to be addressed is the inability to distinguish invasive carcinoma cells from in situ carcinoma when interpreting signals on cytology specimens from primary tumors. Therefore, careful selection of the samples, which are suitable for submission to SISH, is crucial to the optimization of results. No such problem exists for metastastic lesions, as pleural effusions or lymph node metastases.
The major practical limitation of the SISH technique on the cytologic specimen was the presence of too few tumor cells on some scarcely cellular samples and the fact that some cells on the smear might also get lost during processing. Another difficulty faced in this study was a reliable distinction of cancer cells from nonmalignant epithelial cells and lymphocytes in faintly counterstained SISH specimens. The comparison with the hematoxylin/ eosin or Papanicolaou stain was very helpful in these cases. Air drying and other artifacts (which are more common in cytologic than histologic samples) can also hinder correct SISH evaluation. It was also notable that the cases with discrepantly nonamplified SISH results were at least 1 year old or older and consisted of direct smears and not cell block specimens. This fact suggests a diminished sensitivity of the SISH after longer storage times of direct smears and confirms the value of preserving parts of cytologic samples in the form of cell blocks for later ancillary studies. However, our review of these cases concludes that heterogeneity of the tumor in terms of Her-2/neu gene amplification is the main factor leading to discrepancies, especially when analyzing small amounts of cancer cells.
We conclude that the determination of the Her-2/ neu gene amplification status in cytologic breast cancer specimens using automated SISH is a reliable and consistent technique, well suited for routine application in surgical pathology, if the evaluation of Her-2 status is indicated. Different specimen preparations and tissue origins were taken together. FISH indicates fluorescence in-situ hybridization; SISH, silver-enhanced in-situ hybridization.
